Royalty Pharma

$39.78 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Royalty Pharma

Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Stock Analysis

last close $40.51
1-mo return -8.1%
3-mo return 2.8%
avg daily vol. 2.36M
52-week high 47.1
52-week low 34.86
market cap. $17.4B
forward pe 13.5
annual div. 0.76
roe 11.3%
ltg forecast 11.2%
dividend yield 1.88%
annual rev. $2.3B
inst own. 64.3%

Subscribe now for daily local and international financial news